Supporting Information for the Communication entitled

Enantioselective Synthesis of "Quaternary" 1,4-Benzodiazepine-2-ones via Memory of Chirality

Paul R. Carlier*, Hongwu Zhao, Joe DeGuzman, Polo C.-H. Lam Department of Chemistry Virginia Tech Blacksburg, VA 24061 pcarlier@vt.edu

Table of Contents:

Section	Description	Page
А	Experimental Procedures	1
B.	Tabulation of chiral stationary phase HPLC conditions and	8
	retention times	
C.	Computational Details, Absolute Energies, and Cartesian	9
	Coordinates for Calculated Structures	
D.	¹ H and ¹³ C NMR Spectra, HPLC Chromatograms	
	HPLC chromatograms for 2a	16
	HPLC chromatograms for 2b	18
	¹ H, ¹³ C NMR spectra, HPLC chromatograms for 2c	20
	HPLC chromatograms for 3a	24
	¹ H, ¹³ C NMR spectra, HPLC chromatograms for 3 c	26
	¹ H, ¹³ C NMR spectra, HPLC chromatograms for 4	30
	¹ H, ¹ H- ¹ H COSY, ¹ H- ¹ H EXSY, ¹³ C NMR spectra, HPLC	34
	chromatograms for 5 (from $(3S)$ - 2c)	
	¹ H, ¹³ C NMR spectra, HPLC chromatograms for 6	42
	¹ H, ¹³ C NMR spectra, HPLC chromatograms for 7	46
	¹ H, ¹³ C NMR spectra, HPLC chromatograms for 8	50
	¹ H, ¹³ C NMR spectra, HPLC chromatograms for 9	54
	¹ H, ¹³ C NMR spectra, HPLC chromatograms for 10	58
	¹ H spectrum for 11 (α -Me-Phe)	62
	¹ H spectrum for 12 (α -Me-(4-Me-C ₆ H ₄)-Ala)	63
	^{1}H , ^{13}C spectra for 1c	64

A. Experimental Procedures

General

THF was distilled from Na/benzophenone immediately before use. (*S*)-Boc-Ala and (*S*)-Boc-Phe were purchased from Advanced ChemTech and were used as received. Compounds **1a** and **1b** were prepared according to the literature method.¹ Compounds (*3S*)-**2a** and (*3S*)-**3a** were prepared in 91 and 67% yield from (*S*)-Boc-Ala and (*S*)-Boc-Phe using a modification of Shea's protocol;² enantiomeric excess of these compounds was assessed by HPLC (Chiralcel AD and OD). Isopropyl triflate was prepared according to the literature³ immediately before use and was dispensed as a solution in CCl₄. ¹H NMR Spectra were recorded at 500 and 400 MHz; the

corresponding ¹³C NMR resonant frequencies were 125 and 100 MHz respectively. High resolution mass spectra were recorded under FAB conditions (NBA. PEG); in each case the expected molecular formula (M+1, ³⁵Cl) gave the closest match among all possible formulas.

General procedure for N-alkylation of N-H-1,4-benzodiazepine-2-ones

At 0 °C to a stirred solution of (3S)-**2a** (5.1 mmol, 1.0 equiv.) in dry THF (30.0 mL) was added NaH (5.7 mmol, 1.12 equiv., 60% suspension in mineral oil) in one portion. The resulting solution was stirred at 0 °C for 30 min before the dropwise addition of alkyl triflate (15 mmol, 3.0 equiv.). The reaction mixture was stirred for a further 10 min at 0 °C, at which point TLC (1:5 EtOAc:hexanes) indicated the reaction was complete. The reaction was quenched at 0 °C with 20 ml of saturated aqueous NH₄Cl solution, and extracted with CH_2Cl_2 (3 x 30 mL). The combined extracts were dried over anhydrous Na₂SO₄, filtered, and concentrated. The crude product was purified by flash column chromatography on silica gel.

N-i-Pr benzodiazepine 1c

The procedure above was followed with **1a** (102 mg, 0.376 mmol) in anhydrous THF (2 mL), HMPA (390 μ L, 2.26 mmol), NaH (0.451 mmol), *i*-PrOTs (241.7 mg, 1.13 mmol). After stirring overnight, aqueous workup and chromatography (20% EtOAc/Hexane) afforded 65.2 mg (55%) of **1c** as a yellow oil.

¹H NMR (CDCl₃) δ 1.21 (d, *J* = 7.1 Hz, 3H), 1.50 (d, *J* = 6.7 Hz, 3H), 3.73 (d, *J* = 10.5 Hz, 1H), 4.55 (m, *J* = 6.9 Hz, 1H), 4.75 (d, *J* = 10.5 Hz, 1H), 7.27 (s, 1H), 7.37-7.50 (m, 5H), 7.61 (m, 1H); ¹³C NMR (CDCl₃) δ 20.62, 22.39, 51.08, 58.05, 125.23, 128.59, 129.31, 129.55, 130.42, 130.72, 130.76, 132.44, 138.16, 140.72, 168.68, 169.52;

HRMS (FAB) calcd for $C_{18}H_{18}N_2OC1 [M + H]^+$ 313.1108, found 313.1123 (+4.8 ppm, +1.5 mmu)

N-Me benzodiazepine (3S)-2b

The procedure above was followed with (3S)-**2a** (0.12g, 0.42 mmol) in anhydrous THF (2.0 mL), 60% NaH (19 mg, 0.47 mmol) and methyl triflate (58 μ L, 0.51mmol). Purification with flash column chromatography on silica gel (1:2 Hexanes/EtOAc) provided 118 mg (94%) of (3S)-**2b**, which was identical by ¹H NMR to the literature material.⁴ Chiral stationary phase HPLC (Chiralcel AD) indicated 100 %ee.

N-i-Pr benzodiazepine (3S)-2c

The procedure above was followed with (3S)-2a (1.44 g, 5.08 mmol) in anhydrous THF (30.0 ml), 60% NaH (228.0 mg, 5.69 mmol) and isopropyl triflate (2.92 g, 15.2 mmol, solution in 2 mL CCl₄). Purification with flash column chromatography on silica gel (1:5 Hexanes/EtOAc) provided 1.36 g (82%) of (3S)-2c as a white solid, mp 113.8 –114.9 °C.

¹H NMR (CDCl₃): δ 7.61-7.58 (m, 2H), 7.48-7.35 (m, 5H), 7.25 (s, 1H), 4.55 (septet, *J* = 6.9 Hz, 1H), 3.67 (q, *J* = 6.4 Hz, 1H), 1.69 (d, *J* = 6.4 Hz, 3H), 1.48 (d, *J* = 6.9 Hz, 3H), 1.20 (d, *J* = 7.1 Hz, 3H).

¹³C NMR (CDCl₃): δ 170.8, 166.6, 140.4, 138.1, 133.0, 130.64, 130.58, 130.3, 129.4, 129.3, 128.6, 125.3, 59.7, 51.4, 22.3, 20.7, 17.3.

HRMS calcd. for $C_{19}H_{20}CIN_2O$ (M+1) 327.1264, found 327.1264.

 $[\alpha]_{D}^{21}$ = +222.7° (c = 0.55, CHCl₃). Chiral stationary phase HPLC (Chiralcel AD) indicated 100 %ee.

N-i-Pr Benzodiazepine (3S)-3c

The procedure above was followed with (3S)-**3a** (0.683 g, 1.89 mmol) in anhydrous THF (14 mL), 60% NaH (84.7 mg, 2.12 mmol) and isopropyl triflate (1.0921g, 5.68 mmol (neat)). Purification with flash column chromatography on silica gel (1:4 EtOAc:hexanes) provided 0.439 g (58%) of (3S)-**3c** as a pale yellow solid, mp 67-69 °C.

¹H NMR (CDCl₃): δ 7.56-7.15 (several multiplets, 13H), 4.58 (septet, *J* = 6.9 Hz, 1H), 3.70 (dd, *J* = 8.2, 5.4 Hz, 1H), 3.586 (dd, *J* = 13.9, 8.2 Hz, 1H), 3.525 (dd, *J* = 13.9, 5.4 Hz, 1H), 1.56 (s, 3H), 1.47 (d, *J* = 6.7 Hz, 3H), 1.19 (d, *J* = 7.1 Hz, 3H).

¹³C NMR (CDCl₃): 169.8, 166.8, 140.2, 139.5, 138.1, 132.7, 130.66, 130.62, 130.4, 129.9, 129.39, 129.33, 128.5, 128.2, 126.1, 125.4, 66.0, 51.5, 37.8, 22.3, 20.6.

HRMS: calcd for $C_{25}H_{23}N_2OCl (M+1) 403.1577$, found 403.1583 (+1.4 ppm, +0.6 mmu). [α]²¹_D= +64.4° (c = 0.5, CHCl₃). Chiral stationary phase HPLC (Chiralcel AD) indicated 100 %ee.

General Protocol for the C3-alkylation of 3-alkyl-1,4-benzodiazepine-2-ones.

At -78 °C under nitrogen, to a stirred solution of (3S)-2c (0.15mmol, 1.0 equiv) and HMPA (0.90 mmol, 6.0 equiv) in anhydrous THF (3.0 mL) was added LDA (0.15 mmol, 1.2 equiv, 1.5 M in hexanes). After 15 minutes, *n*-BuLi (0.15 mmol, 1.2 equiv, 2.5 M in hexanes) was added and the mixture stirred for a further 15 min. The electrophile (1.5 mmol, 10 equiv.) was then added dropwise via syringe at -78 °C and the reaction was stirred at -78 °C until the starting benzodiazepine was consumed (TLC). The reaction was quenched at -78 °C by the addition of saturated aqueous NH₄Cl (5.0 mL) and extracted with CH₂Cl₂ (3 x 10 mL). The combined extracts were dried over anhydrous Na₂SO₄, filtered, and concentrated. The crude product was purified by flash column chromatography on silica gel.

N-Me Benzodiazepine benzylation product (±)-4

The procedure above was followed with (3S)-**2b** (44.0 mg, 0.15mmol), HMPA (155 μ L, 0.90 mmol), LDA (118 μ L, 0.18 mmol, 1.5M in hexanes), *n*-BuLi (71.0 μ L, 0.18 mmol, 2.5M in hexanes) and benzyl bromide (176.8 μ L, 1.5 mmol). The reaction mixture was stirred at -78 °C for 3 h. Purification with flash column chromatography on silica gel (1:5 Hexanes/EtOAc) provided 37.5 mg (72%) of (±)-**4** as a colorless oil.

¹H NMR (CDCl₃) indicated a 56:44 mixture of the axial-Me and equatorial-Me conformers: δ 7.6-7.1 (m, 12H), 6.85 (br d, J = 6.0 Hz, 1H), 3.71 (d, J = 13.5, 1H × 0.56 ax-Me), 3.48 (s, 3H × 0.44 eq-Me), 3.46 (s, 3H × 0.56 ax-Me, overlapping with signal at 3.48), 3.28 (d, J = 13.3, 1H × 0.56 ax-Me) 2.58 (d, J = 13.5 Hz, 1H x 0.44 eq-Me), 2.52 (d, J = 13.5 Hz, 1H x 0.44 eq-Me), 1.75 (s, 3H × 0.44 eq-Me), 0.79 (s, 3H × 0.56 ax-Me)

³C NMR (CDCl₃) was consistent with an approximate 1:1 mixture of axial-Me and equatorial-Me conformers (35 resonances found for a possible 2 x 20 unique carbons): 173.9, 172.9, 165.5, 164.9, 142.4, 139.9, 138.4, 136.6, 132.3, 131.8 (2 partially resolved peaks), 131.7, 131.5, 130.4, 129.9, 129.8, 129.5, 128.9, 128.7, 128.5, 128.33, 128.26, 127.5, 126.7, 126.3, 122.4, 122.2, 67.9, 65.8, 47.7, 37.7 (2 partially resolved peaks), 37.5, 28.3, 17.6; HRMS calcd. for $C_{24}H_{22}CIN_2O$ (M+1) 389.1421, found 389.1419.

Chiral stationary phase HPLC (Chiralcel AD-H) indicated 0 % ee.

(3R)-5 from Ala-derived benzodiazepine (3S)-2c

The general procedure was followed with (3S)-2c (16.6 mg, 0.05mmol), HMPA (53.4 μ l, 0.30 mmol), LDA (41 μ L, 0.06 mmol, 1.5M in hexanes), *n*-BuLi (25 μ L, 0.06 mmol, 2.5M in hexanes) and benzyl bromide (61 μ L, 0.50 mmol). The reaction mixture was stirred at -78 °C for 3 h.

Purification with flash column chromatography on silica gel (1:6 Hexanes/EtOAc) provided 23.7 mg (74%) of (3R)-**5** as a colorless oil.

¹H NMR (CDCl₃) indicated a 55:45 mixture of the axial-Me and equatorial-Me conformers: δ 7.60-7.15 (m, 12H), 6.94-6.86 (m, 1H), 4.62-4.52 (two overlapping septets, 1H), 3.74 (d, *J* = 13.5 Hz, 1H × 0.55 ax-Me), 3.22 (d, *J* = 13.5 Hz, 1H × 0.55 ax-Me), 2.54 (d, *J* = 13.9 Hz, 1H × 0.45 eq-Me), 2.39 (d, *J* = 13.8 Hz, 1H × 0.45 eq-Me), 1.71 (s, 3H × 0.45 eq-Me), 1.54 (two overlapping doublets, *J* = 6.9 Hz, 6H × 0.45 eq-Me), 1.33 (d, *J* = 7.1 Hz, 3H × 0.55 ax-Me), 1.29 (d, *J* = 7.1 Hz, 0.55 ax-Me), 0.72 (s, 3H × 0.55 ax-Me).

 $^{1}\text{H}-^{1}\text{H}$ COSY (CDCl₃): Among other correlations, spin-coupling between the following benzylic protons is evident: δ 3.74 and 3.22; δ 2.54 and 2.39.

¹H-¹H EXSY (CDCl₃): EXSY confirms that the two species present in solution interconvert, consistent with our assignment as (*M*)- and (*P*)-conformers. Chemical exchange between the following equatorial and axial diastereotopic benzylic protons is evident: δ 3.74 and 2.39; δ 3.22 and 2.54. Chemical exchange between the accidentally equivalent isopropyl methyls (2) at δ 1.54 with the diastereotopic methyls at δ 1.33 and 1.29 is seen. Finally, chemical exchange between the equatorial Me at δ 1.71 and the axial Me at 0.72 is also evident. See end of experimental section of the Supporting Information for determination of exchange rate.

¹³C NMR (CDCl₃) was consistent with an approximate 1:1 mixture of axial-Me and equatorial-Me conformers (44 resonances found for a possible 2 x 22 unique carbons): δ 173.4, 172.1, 165.3, 164.9, 140.64, 140.58, 139.77, 139.7, 138.6, 137.0, 134.2, 133.9, 132.3, 131.1, 130.8, 130.43, 130.40, 129.9, 129.77, 129.71, 129.47, 129.45, 129.39, 129.2, 128.5, 128.4, 128.2, 127.5, 126.7, 126.2, 124.7, 124.6, 68.5, 66.3, 53.6, 53.3, 47.6, 37.7, 28.5, 22.3, 22.0, 20.8, 20.6, 17.6. HRMS calcd. for C₂₆H₂₆ClN₂O (M+1) 417.1734, found 417.1743 (+2.2 ppm, +0.9 mmu). $[\alpha]^{24}{}_{D}$ = +31.4° (c = 0.15, CHCl₃). Chiral stationary phase HPLC (Chiralcel AD-H) indicated 97 %ee. Conversion to the corresponding quaternary amino acid confirmed (*R*)-stereochemistry (see below).

(3S)-5 from Phe-derived benzodiazepine (3S)-3c

The general procedure was followed with (3S)-**3c** (50 mg, 0.124 mmol), HMPA (130 μ L, 0.745 mmol), LDA (99 μ L, 0.149 mmol, 1.5M in hexanes), *n*-BuLi (60 μ L, 0.149 mmol, 2.5M in hexanes) and methyl iodide (77 μ L, 1.24 mmol). The reaction mixture was stirred at –78 °C for 2.5 hours. Purification with flash column chromatography on silica gel (1:6 EtOAc:hexanes) provided 32.9 mg (64%) of (3S)-**5** as a pale yellow oil.

Chiral stationary phase HPLC (Chiralcel AD-H) indicated 96 %ee and (3S)-stereochemistry (comparison with (3R)-**5** synthesized from (3S)-**2c** above).

(*3R*)-6

The general procedure was followed with (3S)-**2c** (50.0 mg, 0.15mmol), HMPA (160 µL, 0.90 mmol), LDA (123 µL, 0.18 mmol, 1.5M in hexanes), *n*-BuLi (74 µL, 0.18 mmol) and 4-methylbenzyl bromide (284.5 mg, 1.5 mmol). The reaction mixture was stirred at -78 °C for 6 h. Purification with flash column chromatography on silica gel (1:8 Hexanes/EtOAc) provided 45.0 mg (68%) of (3*R*)-**6** as a colorless oil,

¹H NMR (CDCl₃) indicated a 53:47 ratio of axial-Me and equatorial-Me conformers: δ 7.58 (t, J = 7.1 Hz, 2H), 7.50-7.06 (unassigned aromatic protons, 8H), 7.01 (d, J = 8.0 Hz, 1H), 6.79 (d, J = 8.0 Hz, 1H), 4.60-4.53 (two overlapping septets, 1H), 3.70 (d, J = 13.6 Hz, 1H × 0.53 ax-Me), 3.17 (d, J = 13.5 Hz, 1H × 0.53 ax-Me), 2.49 (d, J = 13.7 Hz, 1H × 0.47 eq-Me), 2.35 (s, 3H × 0.53 ax-Me),

2.33 (d, J = 13.7 Hz, 1H × 0.47 eq-Me), 2.28 (s, 3H × 0.47 eq-Me), 1.70 (s, 3H × 0.47 eq-Me), 1.56-1.52 (m, 6H x 0.53 ax-Me), 1.327 (d, J = 6.8 Hz, 3H x 0.47 eq-Me), 1.289 (d, J = 6.8 Hz, 3H x 0.47 eq-Me), 0.71 (s, 3H × 0.52 ax-Me).

¹³C NMR (CDCl₃) was consistent with an approximate 1:1 mixture of conformers (44 resonances found for a possible 2 x 23 unique carbons): δ 173.4, 172.3, 165.2, 164.8, 140.7, 140.6, 139.8, 139.7, 136.2, 135.7, 135.4, 134.3, 133.9, 133.8, 132.1, 131.0, 130.8, 130.4, 129.9, 129.7, 129.6, 129.5, 129.4, 129.2, 128.9, 128.5, 128.4, 128.3, 124.7, 124.6, 68.6, 66.3, 53.6, 53.2, 47.1, 37.3, 28.4, 22.3, 22.0, 21.2, 21.1, 20.7, 20.6, 17.6.

HRMS calcd. for $C_{27}H_{28}CIN_2O$ (M+1) 431.1890, found 431.1892 (+0.4 ppm, +0.2 mmu). $[\alpha]^{21}{}_{D}$ = +31.2° (c= 0.16, CHCl₃). Chiral stationary phase HPLC (Chiralcel AD-H) indicated 95 %ee. Stereochemistry assigned as (*R*)- based on the sign of rotation of the corresponding quaternary amino acid (see below).

(*3R*)-7

The general procedure was followed with (3*S*)-**2c** (50.0 mg, 0.15mmol), HMPA (160 μ L, 0.90 mmol), LDA (123 μ L, 0.18 mmol), *n*-BuLi (74 μ L, 0.18 mmol) and 2-phenylbenzyl bromide (284.5 mg, 1.5 mmol). The reaction mixture was stirred at –78 °C for 10 h. Purification with flash column chromatography on silica gel (1:8 Hexanes/EtOAc) provided 53.0 mg (70%) of (3*R*)-**7** as a colorless oil.

¹H NMR (CDCl₃) indicated a 50:50 mixture of axial-Me and equatorial-Me conformers: δ 8.11 (dd, $J = 7.8, 1.2 \text{ Hz}, 1\text{H} \ge 0.5$), 7.58-6.99 (unassigned protons, 16.5 H), 4.56 (septet, $J = 7.1 \text{ Hz}, 1\text{H} \ge 0.50$), 4.49 (septet, $J = 6.9 \text{ Hz}, 1\text{H} \ge 0.50$), 3.68 (d, $J = 13.5 \text{ Hz}, 1\text{H} \ge 0.5 \text{ ax-Me}$), 3.63 (d, $J = 13.5 \text{ Hz}, 1\text{H} \ge 0.5 \text{ ax-Me}$) 2.51 (apparent s, actually collapsed AB pattern of benzylic protons of eq-Me conformer, 2H ≥ 0.5), 1.54 (d, $J = 6.9 \text{ Hz}, 3\text{H} \ge 0.5$), 1.46 (d, $J = 6.7 \text{ Hz}, 3\text{H} \ge 0.5$), 1.40 (s, 3H $\ge 0.5 \text{ eq-Me}$), 1.29 (d, $J = 7.1 \text{ Hz}, 3\text{H} \ge 0.5$), 1.21 (d, $J = 7.1 \text{ Hz}, 3\text{H} \ge 0.5$), 0.33 (s, 3H $\ge 0.50 \text{ ax-Me}$).

¹³C NMR (CDCl₃) was consistent with a 1:1 mixture of conformers (55 resonances found for a possible 2 x 28 unique carbons): δ 172.8, 172.1, 165.0, 164.5, 144.1, 143.2, 142.8, 141.7, 140.6, 140.5, 139.9, 139.5, 135.9, 134.7, 134.0, 133.9, 133.6, 131.0, 130.7, 130.6, 130.4, 130.3, 130.1, 129.9, 129.8, 129.7, 129.5, 129.4, 129.3, 129.2, 129.1, 128.4, 128.21, 128.19, 128.16, 127.2, 126.9, 126.5, 126.37, 126.30, 126.2, 124.7, 124.6, 69.0, 67.3, 53.5, 53.2, 42.4, 33.6, 28.0, 22.2, 22.0, 20.8, 20.5, 17.2.

HRMS calcd. for $C_{32}H_{30}CIN_2O$ (M+1) 493.2047, found 493.2051 (+0.9 ppm, +0.4 mmu). [α]²⁴_D= +163.7° (c = 0.14, CHCl₃). Chiral stationary phase HPLC (AD-H) indicated 99% ee. The stereochemistry is assumed to be (*R*) based on other retentive alkylations.

(*3R*)-8

The general procedure was followed with (3S)-**2c** (145.8 mg, 0.45mmol), HMPA (481 µl, 2.69 mmol), LDA (370 µL, 0.54 mmol, 1.5M in hexanes), *n*-BuLi (221 µL, 0.54 mmol, 2.5M in hexanes) and allyl bromide (350 µL, 4.5 mmol). The reaction mixture was stirred at –78 °C for 4 h. Purification with flash column chromatography on silica gel (1:10 Hexanes/EtOAc) provided 124.7 mg (76%) of (*3R*)-**8** as a colorless oil,

¹H NMR (CDCl₃) indicated a 50:50 mixture of axial-Me and equatorial-Me conformers: δ 7.62-7.55 (m, 2H), 7.48-7.37 (m, 4H), 7.31 (dd, J = 8.7, 5.5 Hz, 1H), 7.19 (dd, J = 7.6 Hz, 2.6 Hz, 1H), 6.29-6.20 (m, 1H × 0.5), 5.61-5.52 (m, 1H × 0.5), 5.22 (apparent d, J = 16.3 Hz, 1H × 0.5), 5.17 (apparent d, J = 10.3 Hz, 1H × 0.5), 4.94 (apparent d, J = 10.3 Hz, 1H × 0.5), 4.63 (apparent d, J = 10.3 Hz, 1H × 0.5), 4.94 (apparent d, J = 10.3 Hz, 1H × 0.5), 4.63 (apparent d, J = 10.3 Hz, 1H × 0.5), 4.94 (apparent d, J = 10.3 Hz, 1H × 0.5), 4.63 (apparent d, J = 10.3 Hz, 1H × 0.5), 4.94 (apparent d, J = 10.3 Hz, 1H × 0.5), 4.63 (apparent d, J = 10.3 Hz, 1H × 0.5), 4.94 (apparent d, J = 10.3 Hz, 1H × 0.5), 4.63 (apparent d, J = 10.3 Hz, 1H × 0.5), 4.94 (apparent d, J = 10.3 Hz, 1H × 0.5), 4.63 (apparent d, J = 10.3 Hz, 1H × 0.5), 4.94 (apparent d, J = 10.3 Hz, 1H × 0.5), 4.63 (apparent d, J = 10.3 Hz, 1

16.3 Hz , 1H × 0.5), 4.56-4.45 (two overlapping septets, 1H), 3.101 (dd, J = 13.9, 5.7 Hz, 1H × 0.5 ax-Me), 2.737 (dd, J = 13.9, 8.3 Hz, 1H × 0.5 ax-Me), 1.93-1.83 (m, 2H x 0.5), 1.83 (s, 3H × 0.5 eq-Me), 1.510 (d, J = 3.5Hz, 3H x 0.5), 1.497 (d, J = 3.5 Hz, 3H x 0.5), 1.287 (d, J = 7.1 Hz, 3H x 0.5), 1.267 (d, J = 7.1 Hz, 3H x 0.5), 0.78 (s, 3H × 0.5 ax-Me).

¹³C NMR (CDCl₃) was consistent with a 50:50 mixture of conformers (40 resonances found from 2 x 20 unique carbons): δ 173.1, 172.3, 165.2, 165.0, 140.6, 140.3, 139.6, 139.5, 135.8, 134.1, 133.9, 134.1, 133.9, 132.9, 130.9, 130.8, 130.5, 130.4, 129.8, 129.7, 129.4, 129.34, 129.30, 128.5, 124.8, 124.7, 118.3, 118.0, 67.5, 65.8, 53.4, 53.1, 47.3, 37.2, 28.6, 22.2, 22.1, 20.7, 20.6, 18.0. HRMS calcd. for $C_{22}H_{24}CIN_2O$ (M+1) 367.1577, found 367.1577.

 $[\alpha]_{D}^{24} = +50.0 \text{ (c} = 0.33 \text{ , CHCl}_3\text{)}$. Chiral stationary phase HPLC (Chiralcel OD) indicated 94 %ee. The stereochemistry is assumed to be (*R*) based on other retentive alkylations.

(3S)-10 from (3S)-3c

The general procedure was followed with (3S)-**3c** (20 mg, 0.0496 mmol), HMPA (52 μ L, 0.298 mmol), LDA (40 μ L, 0.0595 mmol, 1.5M in hexanes), n-BuLi (24 μ L, 0.0595 mmol, 2.5M in hexanes) and allyl bromide (43 μ L, 0.496 mmol). The reaction mixture was stirred at -78 °C for 20 minutes. Purification with flash column chromatography on silica gel (1 EtOAc: 8 Hex) provided 12.1 mg (57%) of (3S)-**5** as a pale yellow oil.

¹H NMR (CDCl₃) indicated a 60:40 mixture of conformers: δ 7.6-6.96 (several multiplets, 13H), 6.41-6.32 (m, 1H x 0.4), 5.71-5.62 (m, 1H x 0.6), 5.27 (apparent d, *J* = 10.0 Hz, 1H x 0.4), 5.23 (apparent d, *J* = 16.3 Hz, 1H x 0.4), 5.01 (dd, *J* = 10.0, 1.6 Hz, 1H x 0.6), 4.65 (dd, *J* = 16.8, 1.6 Hz, 1H x 0.6), 4.56 (two overlapped septets, *J* = 6.9 Hz, 1H), 3.67 (d, *J* = 14.6 Hz, 1H x 0.6), 3.39 (d, *J* = 14.6 Hz, 1H x 0.6), 3.03 (complex d, *J* = 14.7 Hz, 1H x 0.4), 2.69 (dd, *J* = 14.7, 8.7 Hz, 1H x 0.4), 2.46 (d, *J* = 14.3 Hz, 1H x 0.4), 2.42 (d, *J* = 14.3 Hz, 1H x 0.4), 1.88 (dd, *J* = 15.0, 6.8 Hz, 1H x 0.6), 1.59-1.54 (m, 1H x 0.6), 1.52 (two overlapped doublets, *J* = 6.9 Hz, 6H x 0.4), 1.30 (d, *J* = 7.0 Hz, 3H x 0.6).

¹³C NMR (CDCl₃) was consistent with a near 1:1 mixture of conformers (48 resonances found for 2 x 24 unique carbons): δ 171.9, 171.6, 165.0, 164.7, 140.4, 140.0, 139.8, 139.6, 138.5, 136.6, 135.9, 134.1, 133.6, 132.9, 132.3, 130.9, 130.50, 130.48, 130.4, 129.8, 129.7, 129.6, 129.5, 129.4, 129.3, 129.2, 128.43, 128.36, 128.2, 127.5, 126.6, 126.3, 124.74, 124.70, 118.4, 118.2, 70.4, 70.0, 53.4, 53.3, 43.2, 42.6, 34.5, 32.5, 22.1, 21.9, 20.5, 20.4.

HRMS: calcd for $C_{28}H_{27}N_2OC1 443.1890$, found 443.1898 (+1.7 ppm, +0.8 mmu). $[\alpha]^{21}_{D} = +72.1^{\circ}$ (c = 0.315, CHCl₃). Chiral stationary phase HPLC (Chiralcel AD-H) indicated 86 %ee. The stereochemistry is assumed to be (*S*) on the basis of other retentive alkylations.

(3S)-9: deuteration of enolate derived from (3S)-2c

A solution of (3S)-2c (16.6 mg, 0.05 mmol) and HMPA (53 μ l, 0.3 mmol) in anhydrous THF (1.0 mL) was cooled to -78 °C under nitrogen in a dry ice-acetone bath and LDA (41.0 μ l, 0.06 mmol, 1.5M in hexanes) was added dropwise via syringe at -78 °C. After the mixture was stirred for 30 min, *n*-BuLi (25 μ l, 0.06 mmol, 2.5M in hexanes) was added and then the reaction mixture was stirred for 20 min. The enolate was quenched at -78 °C with a mixture of deuteriotrifluoroacetic acid and deuterium oxide (4 μ L of D-OTFA in 200.0 μ L of D₂O). Workup and purification with flash column chromatography on silica gel (1:5 Hexanes/EtOAc) provided 14.2 mg (85%) of (3S)-9 as a pale yellow oil (96%D by ¹H NMR).

¹H NMR (CDCl₃) δ 7.62-7.58 (m, 2H), 7.50-7.33 (m, 5H), 7.28-7.25 (m, 1H), 4.56 (septet, *J* = 6.8 Hz), 1.69 (s, 3H), 1.48 (d, *J* = 6.9 Hz, 3H), 1.20 (d, *J* = 7.1 Hz).

¹³C NMR (CDCl₃) δ 170.8, 166.7, 140.4, 138.1, 133.0, 130.64, 130.59, 130.3, 129.4, 129.3, 128.6, 125.3, 59.7 (t, ${}^{1}J_{CD} = 19.6$ Hz), 20.7, 17.1. FABMS *m/z* 328.1 (M+1), [α]²⁴_D = +219.2° (c = 0.37, CHCl₃). Chiral stationary phase HPLC (Chiralcel AD) indicated 99% ee and (*3S*)-stereochemistry

General procedure for hydrolysis of *N-i*-Pr-1,4-benzodiazepine2-ones to the corresponding quaternary amino acids.

The benzodiazepine to be hydrolyzed (0.1 mmol) was combined with hydrochloric acid (9.0M, 2.0mL) in a pressure tube (Teflon screw cap) and heated at 140 °C (bath temperature) for 3 days. Water (2.0 mL) was added and then the mixture was extracted with EtOAc (3 x 3mL). The water layer was separated, concentrated in vacuo and the residue was dissolved in EtOH (2.0 mL). Propylene oxide (0.3 mL) was added, and the resulting solution was heated at reflux for 30 minutes. Upon cooling the precipitated solid was collected and washed with ethyl acetate and acetone, affording the corresponding free amino acid.

(*R*)-α-methylphenylalanine 11

41.6 mg (0.1 mmol) of (3R)-5 was treated as above to afford 9.0 mg of (R)- α -methylphenylalanine 11 (50%).

¹H NMR (d_6 -DMSO) δ 7.60-7.15 (br m, 7H), 2.79 (d, J = 13.7 Hz, 1H), 2.51 (d, J = 13.7 Hz, 1H), 1.23 (s, 3H). This spectrum was identical in every aspect to commercial α -methylphenylalanine. [α]²⁶_D= + 25.6 (c= 1.25, H₂O). Acros (*S*)- α -methylphenylalanine (item# 27543-2500) is levorotatory: [α]²⁵_D= -24.8°, (c = 1.25, H₂O). We thus assign (*R*)-stereochemistry to our synthesized amino acid.

(R)-α-methyl-(4-methylphenyl)alanine 12

33.1 mg (0.77 mmol) of (*3R*)-**6** was treated as above to afford 9.2 mg of α -methyl-(4-methylphenyl)alanine **12** (62%).

¹H NMR (d_6 -DMSO) δ 7.50-6.80 (br m, 6H), 2.96 (d, J = 13.5 Hz, 1H), 2.73 (d, J = 13.5 Hz, 1H), 2.26 (s, 3H), 1.22 (s, 3H).

HRMS: calcd for $C_{11}H_{15}NO_2$ 194.1181, found 194.1185 (+2.0 ppm, +0.4 mmu). [α]¹⁹_D= +16.6° (c= 0.10, H₂O).

The optical rotations of the enantiomers of this compound are not known in the literature—we assigned the (*R*)-configuration based on the positive sign of the optical rotation, and the structural similarity with α -methylphenylalanine **11**.

Dynamic NMR Studies of 1b,1c, and 5

NMR probe temperatures were determined by calibration with ethylene glycol. The barriers to inversion of **1b** and **1c** were determined by achieving coalescence in d_6 -DMSO on a 400 MHz spectrometer. **1b** : T_c (methylene protons) = 117 °C, $\Delta v = 316.4$ Hz, J = 10.8 Hz, $\Delta G^{\ddagger} = 18.0$ kcal/mol (lit.⁵ 17.6 kcal/mol in d_5 -pyridine). **1c**: T_c (*i*-Pr methyl protons) = 159 °C, $\Delta v = 89.4$ Hz, $\Delta G^{\ddagger} = 21.1$ kcal/mol. The barrier to inversion in **5** in CDCl3 at 24 °C was determined by EXSY⁶ (400 MHz), using a mixing time of 1 sec and a relaxation delay of 2 sec. Since the M and P conformers exist in a nearly 1:1 ratio, we made the simplifying assumption that the M->P and P->M exchange rates are equal.

B. Tabulation of HPLC Conditions and Retention Times

Reported retention times are determined from racemic and enantiomerically enriched/pure samples. The HPLC columns are not thermostatted and as a consequence retention times are subject to day to day variability (cf. cpds **2c**, **9**; **9** is the deuterated analogue of **2c**).

compound	column	solvent, flow rate	fast enantiomer (config) retention time	slow enantiomer (config) retention time
2a	AD	10% isopropanol-hexane 1 mL/min	11.0 min (<i>3R</i>)	13.9 min (<i>3S</i>)
3 a	OD	3% isopropanol-hexane 1 mL/min	27.4 min (<i>3R</i>)	30.9 min (<i>3S</i>)
2b	AD	5% isopropanol-hexane 1 mL/min	14.7 min (<i>3R</i>)	16.5 min (<i>3S</i>)
2c	AD	1% isopropanol-hexane 1 mL/min	16.4 min (<i>3R</i>)	18.2 min (<i>3S</i>)
3c	AD	5% isopropanol-hexane 1 mL/min	14.7 min (<i>3R</i>)	16.2 min (<i>3S</i>)
4	AD-H	2% isopropanol-hexane 1 mL/min	19.4 min	24.4
5	AD-H	1% isopropanol-hexane 1 mL/min	20.2 min (<i>3S</i>)	22.6 min (<i>3R</i>)
6	AD-H	1% isopropanol-hexane 1 mL/min	12.8 min (<i>3R</i>)	18.2 min (<i>3S</i>)
7	AD-H	1% isopropanol-hexane 1 mL/min	13.6 min major enantiomer from (<i>3S</i>)- 2c	16.4 min
8	OD	100% hexane 1 mL/min	17.9 min	19.1 min major enantiomer from (<i>3S</i>)- 2c
9	AD	1% isopropanol-hexane 1 mL/min	15.8 min (<i>3R</i>)	16.9 min (<i>3S</i>)
10	AD-H	1% isopropanol-hexane 1 mL/min	13.3 min	14.3 min major enantiomer from (<i>3S</i>)- 3c

C. Computational Details, Absolute Energies, and Cartesian Coordinates for Calculated Structures

B3LYP/6-31G* equilibrium geometries and ring inversion transition structures of the enolates, and single point electronic energies (ε_0) at the B3LYP/6-31+G*//B3LYP/6-31G* level were obtained using Gaussian 98 (v.A.11). Vibrational frequency analysis was used to identify stationary points as minima (no imaginary frequencies) or transition states (1 imaginary frequency). Displacement vectors associated with the sole imaginary frequencies confirmed that the located transition structures were associated with the ring inversion process. The standard Gaussian 98 statistical mechanics calculations were used to determine the enthalpic corrections (H_{corr}) and total entropy (S_{tot}) from the B3LYP/6-31G* vibrational frequencies and temperature (195 K). The free energy correction (G_{corr}) was obtained from G_{corr} = H_{corr} –TS_{tot}; relative free energies ΔG_{195} were obtained by comparing values of ($\varepsilon_0 + G_{corr}$)

	R ₂	structure	ε	H _{corr} (195 K)	S _{tot} (195 K)	G _{corr} (195 K)	ΔG_{195}
			(hartrees)	(kcal/mol)	(cal/molK)	(kcal/mol)	(kcal/mol)
13b	Me	equil. geometry	-841.643735	176.99	106.25	156.3	0
		ring inv. transition structure	-841.624731	176.63	101.80	156.8	12.4
13c	<i>i</i> -Pr	equil. geometry	-920.270594	212.51	114.84	190.1	0
		ring inv. transition structure	-920.243390	212.30	111.76	190.5	17.5

Coordinates for 13b (B3LYP/6-31G* equilibrium geometry)

HEADER

REMARK	13b E	33LYP/6-31G*	equi	librium geo	metry	
HETATM	1	С	1	0.000	0.000	0.000
HETATM	2	С	1	0.000	0.000	1.417
HETATM	3	С	1	1.212	0.000	-0.707
HETATM	4	N	1	-1.249	-0.074	-0.695
HETATM	5	С	1	2.440	-0.045	-0.045
HETATM	6	С	1	1.260	-0.015	2.058
HETATM	7	Н	1	1.191	0.006	-1.792
HETATM	8	С	1	-1.246	-0.724	-1.997
HETATM	9	С	1	-1.243	0.175	2.192
HETATM	10	С	1	-2.084	1.095	-0.638
HETATM	11	С	1	2.458	-0.052	1.351
HETATM	12	Н	1	3.365	-0.075	-0.616
HETATM	13	Н	1	1.284	0.008	3.143
HETATM	14	Н	1	-0.799	-0.119	-2.801
HETATM	15	N	1	-2.194	1.039	1.838
HETATM	16	С	1	-1.389	-0.417	3.532
HETATM	17	С	1	-2.439	1.611	0.665
HETATM	18	0	1	-2.587	1.519	-1.693
HETATM	19	Н	1	-2.279	-0.925	-2.289
HETATM	20	Н	1	-0.698	-1.668	-1.913
HETATM	21	Н	1	3.404	-0.074	1.890

HETATM	22	С		1		-2.313	0.117	4.467
HETATM	23	С		1		-0.690	-1.579	3.940
HETATM	24	С		1		-3.447	2.743	0.648
HETATM	25	С		1		-0.878	-2.146	5.200
HETATM	26	С		1		-2.495	-0.449	5.722
HETATM	27	Н		1		-2.882	0.989	4.163
HETATM	28	Н		1		-0.001	-2.052	3.247
HETATM	29	Н		1		-3.027	3.661	0.211
HETATM	30	Н		1		-3.756	2.959	1.676
HETATM	31	Н		1		-4.337	2.503	0.048
HETATM	32	С		1		-1.777	-1.588	6.112
HETATM	33	Н		1		-0.320	-3.043	5.466
HETATM	34	Н		1		-3.207	0.004	6.411
HETATM	35	Н		1		-1.924	-2.032	7.094
CONECT	1	2	3	4				
CONECT	2	1	6	9				
CONECT	3	1	5	7				
CONECT	4	1	8	10				
CONECT	5	3	11	12				
CONECT	6	2	11	13				
CONECT	7	3						
CONECT	8	4	14	19	20			
CONECT	9	2	15	16				
CONECT	10	4	17	18				
CONECT	11	5	6	21				
CONECT	12	5						
CONECT	13	6						
CONECT	14	8						
CONECT	15	9	17					
CONECT	16	9	22	23				
CONECT	17	10	15	24				
CONECT	18	10						
CONECT	19	8						
CONECT	20	8						
CONECT	21	11						
CONECT	22	16	26	27				
CONECT	23	16	25	28				
CONECT	24	17	29	30	31			
CONECT	25	23	32	33				
CONECT	26	22	32	34				
CONECT	27	22						
CONECT	28	23						
CONECT	29	24						
CONECT	30	24						
CONECT	31	24		o -				
CONECT	32	25	26	35				
CONECT	33	25						
CONECT	34	26						
CONECT	35	32						
END								

Coordinates for 13b (B3LYP/6-31G* ring inversion transition structure) HEADER

 REMARK 13b B3LYP/6-31G*

 REMARK ring inversion transition structure

 HETATM 1 C
 1
 0.000
 0.000

 HETATM 2 C
 1
 0.000
 1.442

 HETATM 3 C
 1
 1.249
 0.000
 -0.650

HETATM	4	Ν		1		-1.148	-0.071	-0.845
HETATM	5	С		1		2.470	-0.179	0.014
HETATM	6	С		1		1.238	-0.296	2.056
HETATM	7	Н		1		1.286	0.127	-1.723
HETATM	8	С		1		-1.162	0.267	2.310
HETATM	9	С		1		-0.907	-0.434	-2.238
HETATM	10	С		1		-2.534	0.166	-0.553
HETATM	11	С		1		2.456	-0.386	1.383
HETATM	12	Н		1		3.396	-0.186	-0.558
HETATM	13	Н		1		1.236	-0.444	3.129
HETATM	14	N		1		-2.431	0.339	1.945
HETATM	15	Н		1		-1.866	-0.681	-2.685
HETATM	16	С		1		-0.984	0.568	3.759
HETATM	17	С		1		-3.059	0.315	0.784
HETATM	18	0		1		-3.313	0.205	-1.523
HETATM	19	Н		1		-0.466	0.388	-2.824
HETATM	20	Н		1		-0.225	-1.291	-2.288
HETATM	21	Н		1		3.368	-0.602	1.936
HETATM	22	С		1		-1.967	0.142	4.684
HETATM	23	С		1		0.064	1.359	4.288
HETATM	24	С		1		-4.565	0.508	0.832
HETATM	25	С		1		0.130	1.684	5.642
HETATM	26	С		1		-1.898	0.462	6.035
HETATM	27	Н		1		-2.799	-0.439	4.300
HETATM	28	Н		1		0.826	1.746	3.618
HETATM	29	Н		1		-5.114	-0.341	0.399
HETATM	30	Н		1		-4.894	1.394	0.269
HETATM	31	Н		1		-4.864	0.625	1.878
HETATM	32	С		1		-0.844	1.235	6.536
HETATM	33	Н		1		0.949	2.309	5.998
HETATM	34	Н		1		-2.674	0.101	6.709
HETATM	35	Н		1		-0.787	1.483	7.594
CONECT	1	2	3	4				
CONECT	2	1	6	8				
CONECT	3	1	5	7				
CONECT	4	1	9	10				
CONECT	5	3	11	12				
CONECT	6	2	11	13				
CONECT	7	3						
CONECT	8	2	14	16				
CONECT	9	4	15	19	20			
CONECT	10	4	17	18				
CONECT	11	5	6	21				
CONECT	12	5						
CONECT	13	6						
CONECT	14	8	17					
CONECT	15	9						
CONECT	16	8	22	23				
CONECT	17	10	14	24				
CONECT	18	10						
CONECT	19	9						
CONECT	20	9						
CONECT	21	11						
CONECT	22	16	26	27				
CONECT	23	16	25	28				
CONECT	24	17	29	30	31			
CONECT	25	23	32	33	01			
CONECT	26	22	32	34				
				01				

CONECT	27	22		
CONECT	28	23		
CONECT	29	24		
CONECT	30	24		
CONECT	31	24		
CONECT	32	25	26	35
CONECT	33	25		
CONECT	34	26		
CONECT	35	32		
END				

Coordinates for 13c (B3LYP/6-31G* equilibrium geometry) HEADER

HEADER						
REMARK	13c E	33LYP/6-31G	* equi	librium geo	metry	
HETATM	1	С	1	0.000	0.000	0.000
HETATM	2	С	1	0.000	0.000	1.414
HETATM	3	С	1	1.210	0.000	-0.712
HETATM	4	N	1	-1.273	-0.022	-0.664
HETATM	5	С	1	2.431	-0.106	-0.050
HETATM	6	С	1	1.255	-0.097	2.061
HETATM	7	Н	1	1.182	0.045	-1.798
HETATM	8	С	1	-1.431	-0.837	-1.880
HETATM	9	С	1	-1.233	0.314	2.154
HETATM	10	С	1	-1.824	1.314	-0.705
HETATM	11	С	1	2.447	-0.166	1.349
HETATM	12	Н	1	3.359	-0.142	-0.617
HETATM	13	H	1	1.281	-0.092	3.147
HETATM	14	Н	1	-0.922	-0.369	-2.742
HETATM	15	N	1	-2.056	1.290	1.766
HETATM	16	С	1	-1.479	-0.242	3.495
HETATM	17	С	1	-2.162	1.883	0.580
HETATM	18	0	1	-2.104	1.854	-1.790
HETATM	19	С	1	-2.922	-0.953	-2.235
HETATM	20	С	1	-0.863	-2.247	-1.664
HETATM	21	H	1	3.392	-0.242	1.884
HETATM	22	С	1	-2.372	0.390	4.395
HETATM	23	С	1	-0.901	-1.458	3.932
HETATM	24	Н	1	-3.471	-1.408	-1.401
HETATM	25	Н	1	-3.046	-1.591	-3.120
HETATM	26	Н	1	-3.345	0.029	-2.446
HETATM	27	H	1	-1.356	-2.722	-0.807
HETATM	28	Н	1	0.213	-2.249	-1.474
HETATM	29	Н	1	-1.053	-2.860	-2.554
HETATM	30	С	1	-2.938	3.183	0.527
HETATM	31	С	1	-1.171	-1.986	5.194
HETATM	32	С	1	-2.637	-0.139	5.652
HETATM	33	Н	1	-2.846	1.308	4.065
HETATM	34	Н	1	-0.244	-2.001	3.260
HETATM	35	Н	1	-2.305	4.026	0.209
HETATM	36	Н	1	-3.330	3.406	1.524
HETATM	37	H	1	-3.769	3.141	-0.191
HETATM	38	С	1	-2.038		6.073
HETATM	39	H	1	-0.706	-2.927	5.487
HETATM	40	H	1	-3.322	0.386	6.317
HETATM	41	Н	1	-2.251	-1.748	7.056
CONECT	1	2 3	4			
CONECT	2	1 6	9			
CONECT	3	1 5	7			

CONECT CONECT CONECT	4 5 6 7	1 3 2 3	8 11 11	10 12 13	
CONECT CONECT	8	3 4	14	19	20
CONECT	9	2	15	16	20
CONECT	10	4	17	18	
CONECT	11	5	6	21	
CONECT	12	5	0	<u> </u>	
CONECT	13	6			
CONECT	14	8			
CONECT	15	9	17		
CONECT	16	9	22	23	
CONECT	17	10	15	30	
CONECT	18	10			
CONECT	19	8	24	25	26
CONECT	20	8	27	28	29
CONECT	21	11			
CONECT	22	16	32	33	
CONECT	23	16	31	34	
CONECT	24	19			
CONECT	25	19			
CONECT	26	19			
CONECT	27	20			
CONECT	28	20			
CONECT	29	20	25	26	27
CONECT	30	17	35	36	37
CONECT	31	23	38 38	39 40	
CONECT CONECT	32 33	22 22	20	40	
CONECT	34	23			
CONECT	35	30			
CONECT	36	30			
CONECT	37	30			
CONECT	38	31	32	41	
CONECT	39	31	01		
CONECT	40	32			
CONECT	41	38			
END					

Coordinates for 13c (B3LYP/6-31G* ring inversion transition structure) HEADER

REMARK 13c B3LYP/6-31G* REMARK ring inversion transition structure

	2		 			
HETATM	1	С	1	0.000	0.000	0.000
HETATM	2	С	1	0.000	0.000	2.860
HETATM	3	С	1	1.254	0.000	0.713
HETATM	4	С	1	-1.154	-0.229	0.774
HETATM	5	С	1	-1.178	-0.236	2.172
HETATM	6	С	1	1.175	0.107	2.120
HETATM	7	Η	1	-2.095	-0.388	0.275
HETATM	8	Η	1	-2.122	-0.400	2.689
HETATM	9	Η	1	2.108	0.248	2.654
HETATM	10	Η	1	0.026	0.074	3.945
HETATM	11	Ν	1	-0.192	0.233	-1.400
HETATM	12	С	1	2.608	-0.105	0.128
HETATM	13	N	1	2.947	0.150	-1.119
HETATM	14	С	1	-1.558	0.510	-1.924

HETATM	15	Н		1		-1.339	0.859	-2.931
HETATM	16	С		1		3.758	-0.569	0.949
HETATM	17	С		1		6.068	-1.518	2.345
HETATM	18	С		1		5.059	-0.083	0.669
HETATM	19	С		1		3.672	-1.564	1.952
HETATM	20	С		1		4.799	-2.027	2.630
HETATM	21	С		1		6.181	-0.541	1.349
HETATM	22	H		1		5.158	0.659	-0.117
HETATM	23	H		1		2.704	-1.995	2.189
HETATM	24	H		1		4.681	-2.804	3.385
HETATM	25	H		1		7.159	-0.126	1.104
HETATM	26	C		1		0.818	0.412	-2.427
		C		1				
HETATM	27					2.244	0.410	-2.209
HETATM	28	0		1		0.408	0.579	-3.593
HETATM	29	С		1		-2.419	-0.747	-2.160
HETATM	30	H		1		-2.745	-1.271	-1.257
HETATM	31	Н		1		-1.849	-1.455	-2.771
HETATM	32	Н		1		-3.321	-0.467	-2.722
HETATM	33	С		1		-2.291	1.688	-1.253
HETATM	34	Н		1		-2.680	1.493	-0.251
HETATM	35	Н		1		-3.138	1.977	-1.890
HETATM	36	Н		1		-1.616	2.549	-1.184
HETATM	37	Н		1		6.946	-1.875	2.880
HETATM	38	С		1		3.052	0.635	-3.476
HETATM	39	Н		1		2.836	1.605	-3.947
HETATM	40	Н		1		2.851	-0.123	-4.248
HETATM	41	Н		1		4.115	0.598	-3.217
CONECT	1	3	4	11				
CONECT	2	5	6	10				
CONECT	3	1	6	12				
CONECT	4	1	5	7				
CONECT	5	2	4	8				
CONECT	6	2	3	9				
CONECT	7	4	5	9				
CONECT	8	5						
	o 9	6						
CONECT								
CONECT	10	2	1 4	20				
CONECT	11	1	14	26				
CONECT	12	3	13	16				
CONECT	13	12	27					
CONECT	14	11	15	29	33			
CONECT	15	14						
CONECT	16	12	18	19				
CONECT	17	20	21	37				
CONECT	18	16	21	22				
CONECT	19	16	20	23				
CONECT	20	17	19	24				
CONECT	21	17	18	25				
CONECT	22	18						
CONECT	23	19						
CONECT	24	20						
CONECT	25	21						
CONECT	26	11	27	28				
CONECT	27	13	26	38				
CONECT	28	26						
CONECT	29	14	30	31	32			
CONECT	30	29						
CONECT	31	29						

CONECT	32	29			
CONECT	33	14	34	35	36
CONECT	34	33			
CONECT	35	33			
CONECT	36	33			
CONECT	37	17			
CONECT	38	27	39	40	41
CONECT	39	38			
CONECT	40	38			
CONECT	41	38			
END					

[1] Sternbach, L. H.; Fryer, R. I.; Metlesics, W.; Reeder, E.; Sach, G.; Saucy, G.; Stempel, A. J. Org. Chem. **1962**, *27*, 3788-3796.

[2] Hart, B. R.; Rush, D. J.; Shea, K. J. J. Am. Chem. Soc. 2000, 122, 460-465.

[3] Beard, C. D.; Baum, K.; Grakauskas, V. J. Org. Chem. **1973**, *38*, 3673-3677.


[4] Sunjic, V.; Kajfez, F.; Stromar, I.; Blazevic, N.; Kolbah, D. *J. Heterocyclic Chem.* **1973**, *10*, 591-599.

[5] Linscheid, P.; Lehn, J.-M. Bull. Chim. Soc. Fr. 1967, 992-997.

[6] Perrin, C. L.; Dwyer, T. J. Chem. Rev. **1990**, *90*, 935-967.



	SAMPLE	INFORMAT	ION
Sample Name:	HWZ-II-P137	Acquired By:	HongWu
Sample Type:	Unknow n	Date Acquired:	3/5/03 1:14:04 PM
Vial:	1	Acq. Method:	10%B Isopropanol
Injection #:	1	Date Processed:	3/5/03 1:44:16 PM
Injection Volume:	10.00 ul	Channel Name:	2487Channel 1
Run Time:	25.00 Minutes	Sample Set Name:	Hongw u



Report Method:	Untitled
----------------	----------

2

13.935

1395552


49.94

67429

44.33



	SAMPLE	INFORMATION	
Sample Name:	HWZ-III-P15	Acquired By:	HongWu
Sample Type:	Unknow n	Date Acquired:	3/5/03 2:04:42 PM
Vial:	1	Acq. Method:	10%B Isopropanol
Injection #:	1	Date Processed:	3/5/03 2:30:59 PM
Injection Volume:	10.00 ul	Channel Name:	2487Channel 1
Run Time:	25.00 Minutes	Sample Set Name:	Hongw u



	RT (min)	Area (µV*sec)	% Area	Height (µV)	% Height
1	13.917	7930531	100.00	387021	100.00




	SAMPLE	INFORMAT	ION
Sample Name: Sample Type: Vial: njection #: njection Volume: Run Time:	HWZ-II-P143 Unknow n 1 1 10.00 ul 30.00 Minutes	Acquired By: Date Acquired: Acq. Method: Date Processed: Channel Name: Sample Set Name:	HongWu 3/13/03 12:04:49 PM 5%B Isopropanol 3/13/03 2:00:01 PM 2487Channel 1 Hongw u
0.45 0.40 0.35 0.30 0.25 0.20 0.15 0.10 0.05 0.00	$CH_3 \rightarrow N \rightarrow H$ $H_3 \rightarrow N \rightarrow H$ $H_1 \rightarrow H$ $H_2 \rightarrow H$ $H_3 \rightarrow H$	26	

		RT (min)	Area (µV*sec)	% Area	Height (µV)	% Height
-	1	14.663	8608993	50.02	432337	52.28
	2	16.547	8603447	49.98	394697	47.72





S 19

	SAMPLE	INFORMAT	ION
Sample Name:	HWZ-⊪ P121	Acquired By:	HongWu
Sample Type:	Unknow n	Date Acquired:	3/13/03 1:00:03 PM
Vial:	1	Acq. Method:	5%B Isopropanol
Injection #:	1	Date Processed:	3/13/03 1:58:04 PM
Injection Volume:	10.00 ul	Channel Name:	2487Channel 1
Run Time:	30.00 Mi nutes	Sample Set Name:	Hongw u



	RT (min)	Area (µV*sec)	% Area	Height (µV)	% Height
1	16.507	7107896	100.00	325693	100.00








S 22


	SAMPLE	INFORMAT	ION
Sample Name:	HWZ-II-P161	Acquired By:	HongWu
Sample Type:	Unknow n	Date Acquired:	2/26/03 12:23:29 PM
Vial:	1	Acq. Method:	1%B
Injection #:	1	Date Processed:	2/26/03 12:48:43 PM
Injection Volume:	10.00 ul	Channel Name:	2487Channel 1
Run Time:	25.00 Minutes	Sample Set Name:	Hongw u



	RT (min)	Area (µV*sec)	% Area	Height (µV)	% Height
1	16.444	6947419	49.90	289950	52.36
2	18.207	6975494	50.10	263840	47.64



	SAMPLE	INFORMAT	ION	
Sample Name:	HWZ-III-P109	Acquired By:	HongWu	
Sample Type:	Unknow n	Date Acquired:	2/26/03 11:32:02 AM	
Vial:	1	Acq. Method:	1%B	
Injection #:	1	Date Processed:	2/26/03 11:57:16 AM	
Injection Volume:	10.00 ul	Channel Name:	2487Channel 1	
Run Time:	25.00 Minutes	Sample Set Name:	Hongw u	



	RT (min)	Area (µV*sec)	% Area	Height (µV)	% Height
1	18.346	1849662	100.00	68272	100.00

Project Name: Joe_Chiral Reported by User: JOE



	S A	MPLE I	NFORMAT	ION	
Sample Name: Sample Type: Vial: Injection #: Injection Volume: Run Time:	JCD-II-73 Unknow n 1 1 10.00 ul 40.00 Minutes		Acquired By: Date Acquired: Acq. Method: Date Processed: Channel Name: Sample Set Name:	JOE 2/7/03 4:21:48 PM 3% B 2/7/03 5:44:12 PM 2487Channel 1 JOE	
0.20 0.18 0.16 0.14 0.12 ⊋ 0.10 0.08 0.06 0.04 0.02 0.00	H-N race	O CH₂Ph H N Ph Cl mic-3a			31.198
0.00	5.00 10.	00 15.00	20.00 Minutes	25.00 30.0	00 35.00

	RT (min)	Area (µV*sec)	% Area	Height (µV)	% Height	
1	27.205	9158208	49.86	193589	53.77	
2	31.198	9209905	50.14	166470	46.23	


 Project Name:
 Joe_Chiral

 Reported by User:
 JOE

 SAMPLE
 INFORMATION


 Sample Name:
 JCD-III-120(6-10)
 Acquired By:
 JOE


Sample Name:	JCD-111-120(6-10)	Acquired By:	JOE
Sample Type:	Unknow n	Date Acquired:	2/7/03 5:02:03 PM
Vial:	1	Acq. Method:	3% B
Injection #:	1	Date Processed:	2/7/03 5:42:20 PM
Injection Volume:	10.00 ul	Channel Name:	2487Channel 1
Run Time:	40.00 Minutes	Sample Set Name:	JOE



	RT Area (min) (µV*se		% Area	Height (µV)	% Height	
1	31.374	5110168	100.00	89533	100.00	

S 25 Brocze






Project Name: Joe_Chiral Reported by User: JOE



	SAMPLE	INFORMAT	ION
Sample Name:	JCD-11-159-175AD	Acquired By:	JOE
Sample Type:	Unknow n	Date Acquired:	4/24/03 12:35:25 PM
Vial:	1	Aca. Method:	5% B
Injection #:	1	Date Processed:	4/24/03 1:25:06 PM
Injection Volume:	10.00 ul	Channel Name:	2487Channel 1
Run Time:	30.00 Minutes	Sample Set Name:	JOE



	RT (min)			Height (µV)	% Height
1	6.975	54925	0.64	5048	1.34
2	8.654	2833	0.03	294	0.08
3	9.970	35070	0.41	2307	0.61
4	10.527	11620	0.14	532	0.14
5	10.911	5919	0.07	[′] 402	0.11
6	11.433	6398	0.07	342	0.09
7	14.659	2340778	27.43	113126	30.00
8	16.181	6046821	70.86	253754	67.30
9	19.229	29593	0.35	1270	0.34


ſ




SAMPLE	INFORMAT	ION
JCD-III-159AD	Acquired By:	JOE
Unknow n	Date Acquired:	3/28/03 1:28:14 PM
2	-	5% B
1		6/9/03 1:38:58 PM
		2487Channel 1 JOE
	B	
O CH ₂ Ph	10:5	
<i>i</i> -Pr		
N N		
`Ph		
(3S)-3c		
		0 737
		21.073
	JCD-III-159AD Unknow n 2 1 10.00 ul 30.00 Minutes H_2 Ph H_2 Ph H_2 Ph H_2 Ph H_2 Ph H_2 Ph H_2 Ph H_2 Ph H_2 Ph	Unknow n Date Acquired: 2 Acq. Method: 1 Date Processed: 10.00 ul Channel Name: 30.00 Minutes Sample Set Name: f - Pr - V + V + V + V + V + V + V + V + V + V

0.00-				<u>\</u>	<u>_</u>	- 2.00	•			ΔΔ		<u>A</u>				
	·	2.00	4.00	6.00	8.00	10.00	12.00	14.00	16.00	18.00	20.00	22.00	24.00	26.00	28.00	30.00
								Minu	utes							

	RT Area (min) (μV*sec)		% Area	Height (µV)	% Height
1	6.977	20358	0.31	1870	0.67
2	10.215	33601	0.51	2252	0.81
3	10.605	13001	0.20	823	0.30
4	10.844	15064	0.23	843	0.30
5	16.255	6325619	95.80	266783	96.02
6	19.216	29933	0.45	1234	0.44
7	20.567	57192	0.87	1643	0.59
8	21.073	108410	1.64	2400	0.86







	SAMPLE	INFORMAT	10 N
Sample Name: Sample Type: Vial: Injection #: Injection Volume: Run Time:	HWZ-II-P147-AD-H Unknow n 1 1 10.00 ul 40.00 Minutes	Acquired By: Date Acquired: Acq. Method: Date Processed: Channel Name: Sample Set Name:	HongWu 5/2/03 2:25:30 PM 2%B 6/6/03 5:45:34 PM 2487Channel 1 Hongw u
0.14		8 13 0	
0.12			
0.10-	O CH ₃		
0.08	CH ₃ -N N		
0.06	Ph	24.373	
0.04-	racemic-4	$ \wedge$	
0.02	CI		
0.00	5.00 10.00 15.00	20.00 25.0	× 0 30.00 35.00 40
5.00	10.00	Minutes	
		leight % (μV) Height	
		35999 79.50	

2 24.373

4332324

49.77


20.50

35069


Project Name: HONGWU Reported by User: HongWu




	SAMPLE	INFORMATION		
Sample Name:	HWZ-IV-P18-AD-H	Acquired By:	HongWu	
Sample Type:	Unknow n	Date Acquired:	5/2/03 5:46:07 PM	
Vial:	1	Acq. Method:	2%B	
Injection #:	1	Date Processed:	5/2/03 6:32:28 PM	
Injection Volume:	10.00 ul	Channel Name:	2487Channel 1	
Run Time:	35.00 Minutes	Sample Set Name:	Hongw u	





	RT (min)			Height (µV)	% Height
1	20.150	7971859	51.69	213123	79.83
2	24.995	7450687	48.31	53841	20.17







S 35








S 38



Project Name: Joe_Chiral Reported by User: JOE



	SAMPLE	INFORMAT	10 N
Sample Name:	HWZ-111-53	Acquired By:	JOE
Sample Type:	Unknow n	Date Acquired:	3/3/03 2:13:25 PM
Vial:	1	Acq. Method:	1% B
Injection #:	1	Date Processed:	3/3/03 4:29:55 PM
Injection Volume:	10.00 ul	Channel Name:	2487Channel 1
Run Time:	120.00 Minutes	Sample Set Name:	JOE




	RT (min)	Area (µV*sec)	% Area	Height (µV)	% Height
1	20.246	23102924	49.98	544191	47.29
2	22.571	23117471	50.02	606565	52.71


Project Name: Joe_Chiral Reported by User: JOE



	SAMPLE	INFORMAT	ION
Sample Name:	HWZ-III-P89	Acquired By:	JOE
Sample Type:	Unknow n	Date Acquired:	3/3/03 6:28:46 PM
Vial:	1	Acq. Method:	1% B
Injection #:	1	Date Processed:	3/4/03 8:34:58 AM
Injection Volume:	10.00 ul	Channel Name:	2487Channel 1
Run Time:	30.00 Minutes	Sample Set Name:	Hongw u




	RI (min)	Area (µV*sec)	% Area	Height (µV)	% Height
1	20.064	41119	1.37	1045	1.26
2	21.829	2958167	98.63	81767	98.74







	SAMPLE	INFORMAT	ION
Sample Name:	HWZ-IV-P13-AD-H	Acquired By:	HongWu
Sample Type:	Unknow n	Date Acquired:	4/25/03 4:49:49 PM
Vial:	1	Acq. Method:	1%B
Injection #:	1	Date Processed:	4/25/03 5:20:04 PM
Injection Volume:	10.00 ul	Channel Name:	2487Channel 1
Run Time:	30.00 Minutes	Sample Set Name:	Hongw u



	RT (min)	Area (µV*sec)	% Area	Height (µV)	% Height
1	12.844	3154779	50.48	125890	75.08
2	18.235	3095214	49.52	41793	24.92




	SAMPLE	INFORMAT	ION	
Sample Name:	HWZ-IV-P15-AD-H	Acquired By:	HongWu	
Sample Type:	Unknow n	Date Acquired:	4/25/03 4:00:47 PM	
Vial:	1	Acq. Method:	1%B	
Injection #:	1	Date Processed:	4/25/03 4:32:16 PM	
Injection Volume:	10.00 ul	Channel Name:	2487Channel 1	
Run Time:	30.00 Minutes	Sample Set Name:	Hongwu	
0.18 0.16	O CH ₃			
0.12 0.10 0.08 0.06	N * N Ph (3R)-6			

18.329 0.00 18.00 20.00 22.00 4.00 12.00 16.00 26.00 28.00 30.00 2.00 6.00 8.00 10.00 14.00 24.00 Minutes

	RT (min)	Area (µV*sec)	% Area	Height (µV)	% Height
1	12.830	5520068	97.59	217745	99.08
2	18.329	136467	2.41	2026	0.92

0.02









	SAMPLE	INFORMAT	ION
Sample Name: Sample Type: Vial: Injection #: Injection Volume: Run Time:	HWZ-IV-P7-AD-H Unknow n 1 1 10.00 ul 30.00 Mi nutes	Acquired By: Date Acquired: Acq. Method: Date Processed: Channel Name: Sample Set Name:	HongWu 4/23/03 3:21:18 PM 1%B 4/23/03 8:08:08 PM 2487Channel 1 Hongw u
0.045		£	
0.040	~	13.046	
0.035	Ph		
0.030	0		
0.025	CH ₃		
₹ 0.020	Pr-NNN	16.350	
0.015	Ph	16	
0.010	racémic-7		
0.005			
0.000			
2.00	4.00 6.00 8.00 10.00 12.0	0 14.00 16.00 18.00 Minutes	20.00 22.00 24.00 26.00 28.00 30.00
		eight % µV) Height	
	·····	3049 71.93	
	2 16.350 1207204 48.32 16	6797 28.07	




	SAMPLE	INFORMAT	ION
Sample Name:	HWZ-IV-P11-AD-H	Acquired By:	HongWu
Sample Type:	Unknow n	Date Acquired:	4/23/03 5:22:57 PM
Vial:	1	Acq. Method:	1%B
Injection #:	1	Date Processed:	4/23/03 6:11:50 PM
Injection Volume:	10.00 ul	Channel Name:	2487Channel 1
Run Time:	25.00 Minutes	Sample Set Name:	Hongw u




	RI (min)	Area (µV*sec)	% Area	Height (µV)	% Height
1	13.677	6756582	99.59	230796	99.25
2	15.691	27898	0.41	1755	0.75








	SAMPLE	INFORMAT	ION
Sample Name:	HWZ-IV-P3-OD	Acquired By:	HongWu
Sample Type:	Unknow n	Date Acquired:	4/17/03 6:28:37 PM
Vial:	1	Acq. Method:	0%B isopropanol
Injection #:	1	Date Processed:	4/17/03 6:58:51 PM
Injection Volume:	10.00 ul	Channel Name:	2487Channel 1
Run Time:	30.00 Mi nutes	Sample Set Name:	Hongw u




	RT (min)	Area (µV*sec)	% Area	Height (µV)	% Height	
1	17.962	3889478	49.94	169555	46.32	
2	19.154	3898105	50.06	196479	53.68	




	SAMPLE	INFORMAT	ION
Sample Name:	HWZ-IV-P5-OD	Acquired By:	HongWu
Sample Type:	Unknow n	Date Acquired:	4/17/03 7:22:17 PM
Vial:	1	Acq. Method:	0%B isopropanol
Injection #:	1	Date Processed:	4/17/03 7:52:31 PM
Injection Volume:	10.00 ul	Channel Name:	2487Channel 1
Run Time:	30.00 Minutes	Sample Set Name:	Hongwu



		RT (min)	Area (µV*sec)	% Area	Height (µV)	% Height
ſ	1	18.234	333203	2.66	15034	3.41
	2	19.424	12187607	97.34	425717	96.59





Project Name: Reported by User:	HONGWU HongWu		S 56	Breeze
	SAMPLE	INFORMATION		
Sample Name: Sample Type: Vial: Injection #: Injection Volume: Run Time:	HWZ-III-P169-AD Unknow n 1 1 10.00 ul 25.00 Mi nutes	Acquired By:HongWuDate Acquired:4/3/03 11:57:0Acq. Method:1%BDate Processed:5/29/03 10:02Channel Name:2487ChannelSample Set Name:Hognw u	58 AM	
0.070 0.060 0.050 0.040 0.030 0.020 0.010 0.000	i-Pr N N Ph Cl racer			
2.00	4.00 6.00 8.00 10.00) 12.00 14.00 16.00 18.00 Minutes	20.00 2	2.00 24.00
	(min) (µV*sec) [%] Area (j	eight % JV) Height		
	1 15.832 1770834 49.35 71	374 52.58		

2

16.986


1817580

50.65

64361


47.42


Project Name: Reported by User:	HONGWU HongWu			S 57 Braze	
		SAMPLE	INFORMAT	ION	
Sample Name:	HWZ-II⊦P	175-AD	Acquired By:	HongWu	
Sample Type:	Unknow n		Date Acquired:	4/3/03 10:14:39 PM	
Vial:	1		Acq. Method:	1%B	
Injection #:	1		Date Processed:	4/3/03 10:48:07 PM	
Injection Volume:	10.00 ul		Channel Name:	2487Channel 1	
Run Time:	25.00 Min	utes	Sample Set Name:	Hongw u	



	RT (min)	Area (µV*sec)	% Area	Height (µV)	% Height
1	15.887	8982	0.37	388	0.49
2	17.132	2402732	99.63	78919	99.51

Report Method: Untitled





S59

Project Name: Joe_Chiral Reported by User: JOE



Sample Name: Sample Type: Vial: Injection #: Injection Volume: Run Time:	JCD-III-177-III-179AD-H Unknow n 1 1 10.00 ul 25.00 Minutes	Acquired By: Date Acquired: Acq. Method: Date Processed: Channel Name: Sample Set Name:	JOE 4/30/03 4:22:52 PM 1% B 4/30/03 5:37:49 PM 2487Channel 1 JOE
0.035 0.030 0.025 0.020	O CH ₂ Ph CH ₂ CHCH ₂ N N Ph	13.272	
0.015	CI		
0.010	10 6.135		
0.0002.00	<u>A</u>		6.00 18.00 20.00 22.00 24.0

	RT (min)	Area (µV*sec)	% Area	Height (µV)	% Height
1	9.135	10899	0.58	520	0.79
2	13.272	708235	37.75	30407	46.21
3	14.280	1157119	61.67	34874	53.0 0


Γ





		SAMPL	E INFORMAT	ION	
	Sample Name: Sample Type: Vial: Injection #:	JCD-III-179AD-H Unknow n 2 1	Acquired By: Date Acquired: Acq. Method: Date Processed:	JOE 4/30/03 5:21:44 PM 1% B 4/30/03 5:52:05 PM	
	Injection Volume: Run Time:	10.00 ul 25.00 Minutes	Channel Name: Sample Set Name:	2487Channel 1 JOE	
AU	0.035 0.030 0.025 0.020 0.015 0.010	O CH ₂ Ph CH ₂ CH Ph Cl 10	Ø		

0.000	 			<i>,</i> ,	<u> </u>	-		÷ ÷				
	 2.00	4.00	6.00	8.00	10.00	12.00 Minute	14.00 s	16.00	18.00	20.00	22.00	24.00

	RT (min)	Area (µV*sec)	% Area	Height (µV)	% Height
1	6.004	24358	1.85	3767	8.87
2	9.088	14706	1.12	1173	2.76
3	12.439	43734	3.32	1657	3.90
4	13.778	1197978	91.00	35261	83.05
5	15.736	35738	2.71	598	1.41







X : parts per Million : 1H

